Arno Therapeutics, Inc.
ARNI
Other OTC0.00
USD
- -
- -
Arno Therapeutics, Inc.
ARNI
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Arno Therapeutics, Inc. functioned as a biopharmaceutical firm, historically dedicated to advancing therapeutic solutions for oncology and other critical medical conditions. The company's development portfolio once featured Onapristone, a type 1 anti-progestin hormone blocker, which was undergoing Phase I/II clinical investigation for treating breast and endometrial cancers, various solid tumors in post-menopausal women, and advanced castration-resistant prostate cancer in men. Additionally, its investigational pipeline included AR-12, an orally administered cancer treatment that had progressed through a Phase I clinical study for solid tumors and hematological malignancies, alongside preclinical evaluations for diverse anti-microbial applications. A further compound, AR-42, represented an innovative oral cancer therapy then in an investigator-initiated Phase I clinical study, targeting hematological malignancies and solid tumors. Arno Therapeutics also held various agreements, including licensing arrangements with entities such as Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation, alongside a co-development pact with Leica Biosystems Newcastle Ltd. However, the company concluded its operations, selling its remaining assets, most notably the rights to Onapristone to Context Biopharma, Inc., and officially initiated a plan of liquidation and dissolution by late 2017. Arno Therapeutics, Inc. subsequently deregistered its common stock and ceased to exist as an operational entity.